Clearmind Medicine annual stock-based compensation
2021
2022
2023
2024
2025
Clearmind Medicine Stock-Based Compensation Growth & History (CMND)
Clearmind Medicine's stock-based compensation was $81,786 for fiscal 2025.
View full Clearmind Medicine company overviewClearmind Medicine annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-10-31 | $81,786 | −$50,716 | −38.28% |
| 2024 | 2024-10-31 | $132,502 | $86,632 | +188.86% |
| 2023 | 2023-10-31 | $45,870 | −$167,429 | −78.49% |
| 2022 | 2022-10-31 | $213,299 | −$406,640 | −65.59% |
| 2021 | 2021-10-31 | $619,939 | — | — |
Clearmind Medicine quarterly stock-based compensation
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-04-30 | $131,252 | −$100,470 | −43.36% |
| Q1 2026 | 2026-01-31 | $1.4M | $1.0M | +271.47% |
| Q4 2025 | 2025-10-31 | $115,640 | — | — |
| Q3 2025 | 2025-07-31 | $77,790 | −$299,489 | −79.38% |
| Q2 2025 | 2025-04-30 | $231,722 | −$58,369 | −20.12% |
| Q1 2025 | 2025-01-31 | $380,738 | $346,734 | +1019.69% |
| Q3 2024 | 2024-07-31 | $377,279 | — | — |
| Q2 2024 | 2024-04-30 | $290,091 | — | — |
| Q1 2024 | 2024-01-31 | $34,004 | — | — |
Clearmind Medicine stock-based compensation trends
Between the periods ended 2021-10-31 and 2025-10-31, Clearmind Medicine's stock-based compensation decreased from $619,939 to $81,786, a change of −$538,153. The latest reported quarter, Q2 2026, shows $131,252.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Clearmind Medicine source filings ↗